Top

BY Sarah Zizinia

Combining a 3D virtual cutting guide with a surgical navigation tool allowed MD Anderson surgeons to perform a complicated pelvic reconstruction more efficiently while increasing the anatomic accuracy and likely durability of the repair.

In this first such case, the combined technology allowed a more precise fit for an implant crafted from the patient’s fibula.

“When there is a really good fit, the survivorship of the...

A 3D image shows the initial tumor in blue, left, the surgical plan in red, and then the reconstruction with a fibula implant in green at right. Image by Materialise.

BY Clayton Boldt, Ph.D.

Cancer’s ability to evolve in response to treatment and develop resistance to available therapies is one of the most significant challenges...

BY Meagan Raeke

Despite the fact that the human papillomavirus (HPV) vaccine has been available in the U.S. for over 10 years and remains the only vaccine...

BY Clayton Boldt, Ph.D.

Glioblastoma (GBM) is not among the most commonly diagnosed cancers in the U.S., but it can certainly be among the most devastating. Of the roughly 15,000 patients diagnosed annually, only 5-10% will survive five years.

The Glioblastoma Moon Shot® is working to change those odds and save the lives of patients with a coordinated, multidisciplinary team of researchers and physicians committed to findings new vulnerabilities, testing...

Glioblastoma Moon Shot® co-leader Frederick Lang, M.D., explains the discover, develop and deploy flagship programs to attack this deadly brain tumor.

BY Clayton Boldt, Ph. D.

Building upon the foundational discovery that the targeted therapy poziotinib is a potent and selective inhibitor of specific EGFR and HER2...

BY Clayton Boldt, Ph. D.

Results from two MD Anderson-led clinical trials indicate that targeted therapies led to significant improvements in progression-free survival...

BY Meagan Raeke

Early results from two MD Anderson studies show promising responses to neoadjuvant (pre-surgical) checkpoint inhibitors in patients with advanced...

BY Jill Russell, Ph.D.

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer globally. Even with multimodality treatment, including surgery...

BY Clayton Boldt, Ph. D.

Repurposing FDA-approved therapies is a cost-effective way to bring new treatments to patients in need, but identifying those drugs with benefits...

BY Meagan Raeke

MD Anderson researchers have developed the first machine learning algorithm to predict acute toxicities in patients receiving radiation therapy...